Physician profile
Bryan E Youree
NPI 1114014248
$1,265.11
in general payments reported to CMS, 2019-2025
13 companies · $51.63 in 2025
The $51.63 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $42.47 · 2021: $231 · 2022: $340 · 2023: $246 · 2024: $226 · 2025: $51.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $465.50 | 2019-2024 | Dovato, Cabenuva |
| Abbvie INC. | $439.93 | 2021-2025 | Avycaz, Teflaro |
| Cumberland Pharmaceuticals, INC. | $113.84 | 2022 | |
| Janssen Biotech, INC. | $34.91 | 2019-2021 | |
| Gilead Sciences, INC. | $33.90 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.00 | 2021 | |
| Abbott Laboratories | $26.41 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $25.70 | 2019 | |
| Emd Serono, INC. | $24.37 | 2022 | |
| Allergan, INC. | $24.11 | 2020 | |
| Insmed, INC. | $21.32 | 2023 | Arikayce |
| Pfizer INC. | $13.61 | 2019 | |
| Smith+Nephew, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Youree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.